These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31871299)

  • 1. Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models.
    Bruno R; Bottino D; de Alwis DP; Fojo AT; Guedj J; Liu C; Swanson KR; Zheng J; Zheng Y; Jin JY
    Clin Cancer Res; 2020 Apr; 26(8):1787-1795. PubMed ID: 31871299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAMA Oncology Patient Page. The Evolution of a Cancer.
    West HJ; Jin JO
    JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing tumor-associated macrophages as aids for cancer immunotherapy.
    Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y
    Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
    Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
    Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sizing up a slow assault on cancer.
    Ledford H
    Nature; 2013 Apr; 496(7443):14-5. PubMed ID: 23552923
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
    Al-Huniti N; Feng Y; Yu JJ; Lu Z; Nagase M; Zhou D; Sheng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):419-427. PubMed ID: 32589767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

  • 12. What, Why, Where, and When: Bringing Timing to Immuno-Oncology.
    Rothschilds AM; Wittrup KD
    Trends Immunol; 2019 Jan; 40(1):12-21. PubMed ID: 30545676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized medicine in oncology: the future is now.
    Schilsky RL
    Nat Rev Drug Discov; 2010 May; 9(5):363-6. PubMed ID: 20431568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
    Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
    Front Immunol; 2019; 10():924. PubMed ID: 31134058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cell senescence: a new frontier in drug development.
    Cairney CJ; Bilsland AE; Evans TR; Roffey J; Bennett DC; Narita M; Torrance CJ; Keith WN
    Drug Discov Today; 2012 Mar; 17(5-6):269-76. PubMed ID: 22314100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of predictive biomarkers in oncology drug development.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016 Aug; 16(8):807-9. PubMed ID: 27282189
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.